Autolus Therapeutics Reports First Quarter 2020 Financial Results and Operational Progress
07 mai 2020 07h00 HE
|
Autolus Therapeutics plc
- Conference Call to be held on May 7, 2020 at 8:30 am EDT/1:30 pm BST- LONDON, May 07, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company...
Autolus Therapeutics to Report First Quarter 2020 Financial Results and Host Conference Call on May 7
01 mai 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces FDA Acceptance of IND Application for AUTO1 for Adult Acute Lymphoblastic Leukemia
16 avr. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...
Autolus Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Progress
03 mars 2020 07h07 HE
|
Autolus Therapeutics plc
- Conference call to be held on March 3, 2020 at 8:30 am EST/1:30 pm GMT - LONDON, March 03, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical...
Autolus Therapeutics to Present at the Cowen 40th Annual Health Care Conference
25 févr. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 3
24 févr. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Presents Encouraging Additional Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers
30 janv. 2020 07h00 HE
|
Autolus Therapeutics plc
- Initial data show encouraging clinical activity with manageable safety profile - No neurotoxicity observed to date in patients treated with AUTO3 + pembrolizumab Data presented at EHA-EBMT 2nd...
Autolus Announces Closing of Public Offering
27 janv. 2020 16h00 HE
|
Autolus Therapeutics plc
LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus’ Chief Scientific Officer, Dr Martin Pulé, to give Keynote Lecture at the EHA-EBMT 2nd European CAR T Cell Meeting
27 janv. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces that...
Autolus Announces Pricing of Public Offering
22 janv. 2020 21h41 HE
|
Autolus Therapeutics plc
LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...